Crossmark

Efficacy and safety of lenalidomide in HIV-associated cryptococcal meningitis patients with persistent intracranial inflammation: an open-label, single-arm, prospective interventional study

Crossref DOI link: https://doi.org/10.1186/s12974-023-02717-w

Published Online: 2023-02-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wan, Zhikai

Tao, Ran

Hui, Jiangjin

Liu, Xiang

Peng, Xiaorong

Guo, Yongzheng

Zhu, Xueling

Huang, Ying

Zhu, Biao
Funding

Funding for this research was provided by:

National Key R&D Program of China (No.2021YFC2301900-2021YFC2301901)

National Special Research Program for Important Infectious Diseases (2017ZX10202102)
License Information

Text and Data Mining valid from 2023-02-15

Version of Record valid from 2023-02-15
More Information

Article History

Received: 2 February 2022

Accepted: 1 February 2023

First Online: 15 February 2023

Declarations

:

: The trial protocol (and other documents) was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University (Zhejiang, China) in accordance with the Helsinki Declaration 1964 and its later amendments. Written informed consent was obtained from all patients. This study is registered with the China Clinical Trial Registry (; ChiCTR1900023184).

: All authors have approved this version of the manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below